Table 3.
Copy number alterations detected in 148 lung neuroendocrine tumours by targeted sequencing of 13 genes according to histotype (related to Figure 2B)
| Gene | TC (n = 53), no. (%) | AC (n = 35), no. (%) | LCNEC (n = 27), no. (%) | SCLC (n = 33), no. (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HD | LOH | G | HD | LOH | G | HD | LOH | G | HD | LOH | G | p‐Value * | Adjusted † p‐value | |
| RB1 | 7 (13.2) | 6 (11.3) | 2 (5.7) | 2 (5.7) | 9 (33.3) | 6 (22.2) | 13 (39.4) | 10 (30.3) | 2.7E‐07 | 1.9E‐06 | ||||
| TP53 | 2 (3.8) | 8 (15.1) | 2 (5.7) | 8 (22.9) | 11 (40.7) | 14 (42.4) | 0.078 | 0.084 | ||||||
| TERT | 3 (5.6) | 15 (42.9) | 5 (18.5) | 17 (51.5) | 1.3E‐06 | 5.6E‐06 | ||||||||
| SDHA | 5 (9.4) | 14 (40.0) | 6 (22.2) | 13 (39.4) | 0.0015 | 0.0032 | ||||||||
| RICTOR | 2 (3.8) | 10 (28.6) | 10 (37.0) | 13 (39.4) | 3.7E‐05 | 0.00012 | ||||||||
| PIK3CA | 2 (3.8) | 4 (11.4) | 9 (33.3) | 17 (51.5) | 2.9E‐07 | 1.9E‐06 | ||||||||
| MYC | 7 (13.2) | 4 (11.4) | 6 (22.2) | 8 (24.2) | 0.37 | 0.37 | ||||||||
| MEN1 | 8 (15.1) | 8 (22.9) | 1 (3.7) | 0.0061 | 0.011 | |||||||||
| SMAD4 | 2 (3.8) | 1 (2.9) | 3 (8.6) | 8 (29.6) | 1 (3.0) | 2 (6.1) | 0.0079 | 0.011 | ||||||
| MYCL | 7 (20.0) | 5 (18.5) | 4 (12.1) | 0.0013 | 0.0032 | |||||||||
| SRC | 4 (11.4) | 3 (11.1) | 3 (9.1) | 0.030 | 0.039 | |||||||||
| FGFR1 | 1 (3.7) | 4 (12.1) | 0.0070 | 0.011 | ||||||||||
| BCL2 | 2 (5.7) | 3 (9.1) | 0.049 | 0.058 | ||||||||||
AC, atypical carcinoid; G, gain; HD, homozygous deletion; LCNEC, large‐cell neuroendocrine carcinoma; LOH, loss of heterozygosity; SCLC, small‐cell lung cancer; TC, typical carcinoid.
*
Comparison of copy number alteration frequency among histotype by Fisher's exact test.
†
Correction for multiple comparisons according to Benjamini–Hochberg.